177 related articles for article (PubMed ID: 19188166)
1. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.
Yang J; Cao Y; Hong S; Li H; Qian J; Kwak LW; Yi Q
Clin Cancer Res; 2009 Feb; 15(3):951-9. PubMed ID: 19188166
[TBL] [Abstract][Full Text] [Related]
2. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
3. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.
Yang J; Zhang X; Wang J; Qian J; Zhang L; Wang M; Kwak LW; Yi Q
Blood; 2007 Oct; 110(8):3028-35. PubMed ID: 17644731
[TBL] [Abstract][Full Text] [Related]
4. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
5. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.
Cao Y; Lan Y; Qian J; Zheng Y; Hong S; Li H; Wang M; Kwak LW; Lin D; Yang J; Yi Q
Br J Haematol; 2011 Jul; 154(1):111-21. PubMed ID: 21554263
[TBL] [Abstract][Full Text] [Related]
6. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
[TBL] [Abstract][Full Text] [Related]
7. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.
Qian J; Wang Q; Xiao L; Xiong W; Xian M; Su P; Yang M; Zhang C; Li Y; Zhong L; Ganguly S; Zu Y; Yi Q
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38267222
[TBL] [Abstract][Full Text] [Related]
8. Modified human beta 2-microglobulin (desLys(58)) displays decreased affinity for the heavy chain of MHC class I and induces nitric oxide production and apoptosis.
Wang M; Harhaji L; Lamberth K; Harndahl M; Buus S; Heegaard NH; Claesson MH; Nissen MH
Scand J Immunol; 2009 Mar; 69(3):203-12. PubMed ID: 19281532
[TBL] [Abstract][Full Text] [Related]
9. Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach.
Niens M; Grier AE; Marron M; Kay TW; Greiner DL; Serreze DV
Diabetes; 2011 Apr; 60(4):1229-36. PubMed ID: 21346176
[TBL] [Abstract][Full Text] [Related]
10. Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development.
Racine JJ; Stewart I; Ratiu J; Christianson G; Lowell E; Helm K; Allocco J; Maser RS; Chen YG; Lutz CM; Roopenian D; Schloss J; DiLorenzo TP; Serreze DV
Diabetes; 2018 May; 67(5):923-935. PubMed ID: 29472249
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
13. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
14. Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities.
Lai J; Tan WJ; Too CT; Choo JA; Wong LH; Mustafa FB; Srinivasan N; Lim AP; Zhong Y; Gascoigne NR; Hanson BJ; Chan SH; Chen J; MacAry PA
Blood; 2016 Sep; 128(10):1396-407. PubMed ID: 27338099
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
[TBL] [Abstract][Full Text] [Related]
16. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
17. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies.
Mulder A; Eijsink C; Kester MG; Franke ME; Kardol MJ; Heemskerk MH; van Kooten C; Verreck FA; Drijfhout JW; Koning F; Doxiadis II; Claas FH
J Immunol; 2005 Nov; 175(9):5950-7. PubMed ID: 16237088
[TBL] [Abstract][Full Text] [Related]
18. Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer.
Sasaki T; Ravindranath MH; Terasaki PI; Freitas MC; Kawakita S; Jucaud V
Int J Cancer; 2014 Apr; 134(7):1558-70. PubMed ID: 24105714
[TBL] [Abstract][Full Text] [Related]
19. "Humanized" HLA transgenic NOD mice to identify pancreatic beta cell autoantigens of potential clinical relevance to type 1 diabetes.
Serreze DV; Marron MP; Dilorenzo TP
Ann N Y Acad Sci; 2007 Apr; 1103():103-11. PubMed ID: 17376821
[TBL] [Abstract][Full Text] [Related]
20. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
